COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
- PMID: 32315980
- PMCID: PMC7156942
- DOI: 10.1016/j.msard.2020.102120
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Abstract
Background: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19.
Methods: In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19.
Results: Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred.
Discussion: This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflicts of interest Giovanni Novi received speaker honoraria from Merck, Novartis and Roche Malgorzata Mikulska received speaker honoraria from MSD, Gilead, Pfizer, Biotest, Janssen; all outside the submitted work. Federica Briano reports no disclosures Federica Toscanini reports no disclosures Francesco Tazza reports no disclosures Antonio Uccelli: received honoraria or consultation fees from Biogen, Roche, Teva, Merck-Serono, Genzyme, Novartis Matilde Inglese received honoraria or consultation fees from Roche, Biogen, Merck-Serono, Genzyme and research grants from NIH, NMSS, FISM, Novartis and Teva Neuroscience
Comment in
-
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.Mult Scler Relat Disord. 2020 Jun;41:102135. doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18. Mult Scler Relat Disord. 2020. PMID: 32339915 Free PMC article. No abstract available.
-
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.Mult Scler Relat Disord. 2020 Jul;42:102185. doi: 10.1016/j.msard.2020.102185. Epub 2020 May 7. Mult Scler Relat Disord. 2020. PMID: 32408147 Free PMC article. No abstract available.
-
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.Mult Scler Relat Disord. 2020 Jul;42:102201. doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15. Mult Scler Relat Disord. 2020. PMID: 32480327 Free PMC article. No abstract available.
-
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.Mult Scler Relat Disord. 2020 Jul;42:102192. doi: 10.1016/j.msard.2020.102192. Epub 2020 May 16. Mult Scler Relat Disord. 2020. PMID: 32570202 Free PMC article. No abstract available.
Similar articles
-
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13. Mult Scler Relat Disord. 2020. PMID: 32460086 Free PMC article.
-
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23. Mult Scler Relat Disord. 2020. PMID: 32464586 Free PMC article. No abstract available.
-
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?Mult Scler Relat Disord. 2020 Jul;42:102196. doi: 10.1016/j.msard.2020.102196. Epub 2020 May 16. Mult Scler Relat Disord. 2020. PMID: 32480326 Free PMC article.
-
Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?Clin Rheumatol. 2020 Jul;39(7):2067-2068. doi: 10.1007/s10067-020-05184-3. Epub 2020 May 30. Clin Rheumatol. 2020. PMID: 32474884 Free PMC article. Review. No abstract available.
-
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12. Mult Scler Relat Disord. 2020. PMID: 32464584 Free PMC article. Review.
Cited by
-
Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.Front Public Health. 2024 Aug 27;12:1421211. doi: 10.3389/fpubh.2024.1421211. eCollection 2024. Front Public Health. 2024. PMID: 39257951 Free PMC article.
-
Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.J Allergy Clin Immunol Glob. 2023 May;2(2):100091. doi: 10.1016/j.jacig.2023.100091. Epub 2023 Mar 15. J Allergy Clin Immunol Glob. 2023. PMID: 37038555 Free PMC article.
-
Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis.J Clin Neurol. 2023 Jul;19(4):381-391. doi: 10.3988/jcn.2022.0348. Epub 2023 Mar 13. J Clin Neurol. 2023. PMID: 36929061 Free PMC article.
-
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.Acta Neurol Belg. 2023 Oct;123(5):1885-1892. doi: 10.1007/s13760-022-02125-6. Epub 2022 Nov 4. Acta Neurol Belg. 2023. PMID: 36331727 Free PMC article.
-
Clinical Implications of COVID-19 Presence in CSF: Systematic Review of Case Reports.Cells. 2022 Oct 13;11(20):3212. doi: 10.3390/cells11203212. Cells. 2022. PMID: 36291083 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources